Lucid Diagnostics (LUCD) Net Cash Flow (QoQ) (2021 - 2026)
Lucid Diagnostics (LUCD) Net Cash Flow (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.95% |
| Dec 31, 2025 | -177.91% |
| Sep 30, 2025 | 175.55% |
| Jun 30, 2025 | 104.34% |
| Mar 31, 2025 | -63.40% |
| Dec 31, 2024 | 175.44% |
| Sep 30, 2024 | -7,007.95% |
| Jun 30, 2024 | -97.43% |
| Mar 31, 2024 | 213.95% |
| Dec 31, 2023 | 39.51% |
| Sep 30, 2023 | -22.55% |
| Jun 30, 2023 | -140.78% |
| Mar 31, 2023 | 482.24% |
| Dec 31, 2022 | 22.37% |
| Sep 30, 2022 | 62.30% |
| Jun 30, 2022 | -165.64% |
| Mar 31, 2022 | -110.70% |
| Dec 31, 2021 | 2,526.92% |
| Sep 30, 2021 | -203.08% |
| Jun 30, 2021 | 9,033.33% |